Publications:30
Shyamala Navada, MD, MSCR
About Me
Dr. Navada is an Adjunct Associate Professor in the Department of Medicine
Language
English
Position
ADJUNCT ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
Research Topics
Cancer, Leukemia
Clinical Focus
- Anemia
- Aplastic Anemia
- Blood Transfusion
- Bone Marrow Biopsy
- Leukemia
- Myelodysplastic Syndromes
- Primary Polycythemia
Publications
Selected Publications
- Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. Mikkael A. Sekeres, Valeria Santini, Maria Díez-Campelo, Rami S. Komrokji, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcárcel-Ferreiras, Esther Natalie Oliva, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Amer M. Zeidan, Uwe Platzbecker. Leukemia and Lymphoma
- Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims. Rami S. Komrokji, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Tim Werwath, Zhuoer Xie, Eric Padron, David A. Sallman. Clinical Lymphoma, Myeloma and Leukemia
- CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs). Yazan Madanat, Michael R. Savona, Mikkael A. Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Fei Huang, Shyamala Navada, Rami S. Komrokji, Amer M. Zeidan. Journal of the National Comprehensive Cancer Network : JNCCN
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Navada during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Outside Employment
- Geron Corporation
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.